The economic impact of symptomatic menopause among low-socioeconomic women in the United States
- 2 August 2015
- journal article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 16 (2) , 305-313
Abstract
Background: Menopausal symptoms have a significant negative impact on patient’s quality of life and increase healthcare costs among women. Methods: This retrospective analysis used data from a U.S. national database (01 January 2008–31 December 2010). Patients with a diagnosis of menopause symptoms or a prescription claim for hormone therapy were matched to control patients. Healthcare resource utilization and costs during the 6-month follow-up period were compared. Generalized linear models were used to adjust for differences in baseline and demographic characteristics between the cohorts. Results: A total of 71,076 patients were included in each cohort. Patients with menopausal symptoms were more likely to have depression and anxiety and incurred significantly higher follow-up healthcare costs ($7237 vs $6739, p < 0.001) and healthcare utilization during the 6-month follow-up period. Conclusion: Patients diagnosed with menopausal symptoms or treated with hormone therapy incurred significantly higher healthcare costs than those without menopausal symptoms or treatment.Keywords
This publication has 31 references indexed in Scilit:
- Vasomotor symptoms and cardiovascular events in postmenopausal womenMenopause, 2011
- Longitudinal association of vasomotor symptoms and psychosocial outcomes among postmenopausal women in the United StatesMenopause, 2010
- Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged womenMenopause, 2009
- Administrative and Claims Records as Sources of Health Care Cost DataMedical Care, 2009
- Presence of vasomotor symptoms is associated with lower bone mineral densityMenopause, 2009
- Depressive symptoms and menopausal burden in the midlifeMaturitas, 2009
- Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society: RetractedMenopause, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- A Comparison of Observational Studies and Randomized, Controlled TrialsNew England Journal of Medicine, 2000
- The prevalence of hot flash and associated variables among perimenopausal womenResearch in Nursing & Health, 1985